Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis by Hallow, K. Melissa et al.
 
 
 
 
 
Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. 
J.V.  and Boulton, D. W. (2018) Why do SGLT2 inhibitors reduce heart 
failure hospitalization? A differential volume regulation 
hypothesis. Diabetes, Obesity and Metabolism, 20(3), pp. 479-487. 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. 
J.V.  and Boulton, D. W. (2018) Why do SGLT2 inhibitors reduce heart 
failure hospitalization? A differential volume regulation 
hypothesis. Diabetes, Obesity and Metabolism, 20(3), pp. 479-
487.(doi:10.1111/dom.13126) 
This article may be used for non-commercial purposes in accordance with 
Wiley Terms and Conditions for Self-Archiving.  
 
 
 
 
http://eprints.gla.ac.uk/149945/ 
     
 
 
 
 
 
 
Deposited on: 17 October 2017 
 
 
 
 
 
A
cc
ep
te
d 
A
rti
cl
e
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential 
volume regulation hypothesis. 
K. Melissa Hallow PhD1,2, Gabriel Helmlinger PhD3*, Peter J. Greasley PhD4, John J. V. 
McMurray MD5, David W. Boulton PhD3** 
1. School of Chemical, Materials, and Biomedical Engineering, University of Georgia, 
Athens, GA USA 
2. Department of Epidemiology and Biostatistics, University of Georgia, Athens, GA USA 
3. Quantitative Clinical Pharmacology, Early Clinical Development, Innovative Medicines, 
AstraZeneca, Waltham, MA* and Gaithersburg, MD** USA 
4. Early Clinical Development, Innovative Medicines, AstraZeneca, Gothenburg, Sweden 
5. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK 
 
Running Title: SGLT2 inhibitors and differential volume regulation 
Corresponding Author: 
K. Melissa Hallow, PhD 
597 D.W. Brooks Drive 
Athens, GA 30602 
404-668-7168  
hallowkm@uga.edu 
 
Key Words: SGLT2 inhibitor, dapagliflozin, cardiovascular disease, diabetes 
complications, antidiabetic drug, renal glucose handling 
 
ABSTRACT 
The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure 
hospitalization in the EMPA-REG OUTCOMES trial has raised the possibility of using 
these agents to treat established heart failure. We hypothesize that osmotic diuresis 
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induced by SGLT2 inhibition, a distinctly different diuretic mechanism than other diuretic 
classes, results in greater electrolyte-free water clearance, and ultimately in greater fluid 
clearance from the interstitial fluid (IF) space than from the circulation, potentially resulting 
in congestion relief with minimal impact on blood volume, arterial filling, and organ 
perfusion. We utilize a mathematical model to illustrate that electrolyte-free water 
clearance results in a greater reduction in IF volume compared to blood volume, and that 
this difference may be mediated by peripheral sequestration of osmotically inactive 
sodium. By coupling the model with data on plasma and urinary sodium and water in 
healthy subjects administered either the SGLT2i dapagliflozin or loop diuretic 
bumetanide, we predict that dapagliflozin produces a 2-fold greater reduction in IF volume 
compared to blood volume, while the reduction in IF volume with bumetanide is only 78% 
of the reduction in blood volume. Heart failure is characterized by excess fluid 
accumulation, in both the vascular compartment and interstitial space, yet many heart 
failure patients have arterial underfilling due to low cardiac output, which may be 
aggravated by conventional diuretic treatment. Thus, we hypothesize that by reducing IF 
volume to a greater extent than blood volume, SGLT2 inhibitors might provide better 
control of congestion without reducing arterial filling and perfusion.   
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INTRODUCTION 
The EMPA-REG OUTCOME trial, which evaluated the SGLT2 inhibitor (SGLT2i) 
empagliflozin in patients with increased cardiovascular risk, demonstrated a large and 
unexpected reduction in cardiovascular mortality, heart failure hospitalization, and all-
cause mortality[1, 2].  More recently, the Canagliflozin Cardiovascular Assessment 
program (CANVAS) showed a similar decrease in heart failure hospitalization although 
the rate of death from cardiovascular causes was not reduced significantly [3]. Differences 
in heart failure hospitalization rates were apparent early, within the first few months in 
both trials, suggesting treatment may have “rescued” individuals on the verge of heart 
failure. This finding was unexpected, and although hypotheses have been proposed [2, 
4], there is no consensus understanding of the mechanism for this protective effect.  
SGLT2 is predominantly located in the proximal tubule (PT) of the kidney, and reabsorbs 
sodium (Na+) and glucose in a 1:1 molar ratio. Thus, SGLT2 inhibition reduces not only 
glucose reabsorption, but PT Na+ reabsorption as well. In addition, SGLT2 inhibition likely 
stimulates an osmotic diuresis effect, particularly in the distal tubule. This is because, 
except in cases of excessive plasma glucose (greater than around 250 mg/dl), nearly all 
filtered glucose is normally reabsorbed in the PT and very little is delivered distally. 
However, with SGLT2i, unreabsorbed glucose flows into the distal nephron, and as water 
is successively reabsorbed along the nephron, glucose concentration and tubular fluid 
osmolality is increased, reducing the osmotic gradient between the tubular fluid and 
interstitium. This reduces passive reabsorption of water, particularly in the collecting duct, 
resulting in osmotic diuresis. Na+ reabsorption may also be reduced through solvent drag.  
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The osmotic diuresis effect of SGLT2i is distinctly different from that of other types of 
diuretics. Most diuretics (thiazide, loop, potassium-sparing diuretics) act by directly 
reducing Na+ reabsorption, and water follows passively. In contrast, the osmotic diuresis 
effect of SGLT2i (in addition to its direct effect on proximal glucose and sodium 
reabsorption) acts to reduce water reabsorption, and Na+ reabsorption is reduced 
indirectly. Thus, SGLT2i may be expected to produce greater electrolyte-free water 
clearance than other Na+-driven diuretics [5, 6]. 
While our understanding of body fluid and sodium has historically focused on the blood 
and interstitial fluid (IFIF) compartments, there has been growing appreciation over the 
last few years for the role of peripheral tissues, in particular the skin, muscle, and the 
skeleton, in dynamically storing and regulating body sodium [7-9]. Titze and colleagues 
have shown that sodium can be stored non-osmotically (without commensurate water 
retention) in the skin and other tissues, likely by binding with glycosaminoglycans. They 
have proposed that skin and other tissues act as negatively charged capacitors, trapping 
and releasing cations[9], effectively mitigating excess sodium and water accumulation or 
loss. For interventions that affect body water and sodium levels, this mechanism may play 
an important role [8, 10].  
Many of the signs and symptoms of heart failure are the result of fluid accumulation in 
the interstitium, leading to peripheral and pulmonary edema, and effective treatment aims 
to reduce this congestion. However, while blood volume and IF volume are both increased 
in heart failure, much of the excess blood is accumulated in the venous system, and 
relative arterial underfilling due to low cardiac output maybe a problem in many patients 
with heart failure [11, 12]. Treatment with diuretics and vasodilators can reduce the 
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effective arterial circulating volume further, limiting the effectiveness of these treatments 
and setting in motion maladaptive compensatory responses [13-16].  
We hypothesize that, as a result of osmotic diuresis and greater electrolyte-free 
water clearance, SGLT2i produces an unexpectedly greater clearance of fluid from the IF 
space, relative to clearance from the circulation, compared with traditional diuretics. In 
this study, we use a mathematical model of blood, IF, and peripheral Na+ and water 
content, coupled with data from healthy volunteers treated with the SGLT2i dapagliflozin 
or with the loop diuretic bumetanide, to demonstrate this hypothesis. We further 
hypothesize that greater reductions in IF volume, relative to blood volume, might allow 
better control of congestion without reducing arterial filling and perfusion in heart failure 
patients. This may explain the early reduction in heart failure events observed in EMPA-
REG and in CANVAS.  
METHODS 
Dapagliflozin/bumetanide pharmacodynamic drug-drug interaction study: Healthy 
subjects (n=42, 10 females and 32 males, aged 19 to 45 years [mean: 30 years], 28 
Caucasian and 14 Black, with BMI values of 20.0 to 31.2 kg/m2 [mean: 26.5 kg/m2]) gave 
written, informed consent to participate in the Institutional Review Board-approved study. 
The subjects were randomized in this open label study to a loop diuretic bumetanide (1 
mg/day), dapagliflozin (10 mg/day), or both for 7 days followed, in all groups, by 7 days 
of bumetanide plus dapagliflozin. Subjects were confined in a clinical trial unit for the study 
duration and received a fixed diet with ~110 mmol/day sodium and 60 mmol/day 
potassium for 2 days prior to and throughout dosing. Pooled 24h urine samples were 
collected on day –1 (baseline) and throughout the study and analyzed for volume, total 
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amounts of sodium, potassium, chloride, calcium, magnesium, phosphorus, glucose, 
creatinine, uric acid and osmolality. Fasting serum samples were obtained at baseline 
and throughout the study for determination of sodium, potassium, chloride, calcium, 
magnesium, phosphorus, bicarbonate, glucose, creatinine, uric acid, blood urea nitrogen 
and osmolality and plasma renin activity (PRA). The urine and plasma samples were 
assayed at an accredited Central Laboratory (PPD Central Laboratory, Austin, Texas, 
USA). The study did not assess plasma or IF volumes. For the purposes of the analyses 
described here, data from bumetanide or dapagliflozin given alone for the first 7 days of 
the study were used. Of note, the salt tablets provided in this study to precisely control 
sodium intake were poorly tolerated and associated with frequent adverse events 
including nausea, vomiting and dizziness. 
Electrolyte-free water clearance (cH2Oe) was calculated from urine volume (Vurine), 
urinary sodium (UNa), urinary potassium (UK), and serum sodium (SNa), according to 
Equation 1. 
 ܿܪଶܱ݁ = ௨ܸ௥௜௡௘ ቀ1 − ௎ಿೌା௎ೖௌಿೌ ቁ Eq. 1 
Total freee water clearance (FWC) was calculated from urine volume, urine osmolality 
(Uosm), and plasma osmolality (Posm), according to Equation 2: 
 ܨܹܥ = ௨ܸ௥௜௡௘ ቀ1 − ௎೚ೞ೘௉೚ೞ೘ቁ Eq, 2 
 
Model: 
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We utilized a mathematical model, as illustrated in Figure 1, to theoretically 
evaluate the impact of free water clearance and osmotically inactive sodium storage on 
blood and IF volume, and to simulate the volume response to dapagliflozin and 
bumetanide. The model consists of three compartments: blood (plasma and red blood 
cells), interstitial fluid, and a peripheral Na+ storage compartment. The peripheral 
compartment is a non-fluid compartment representing the Na+ stored non-osmotically in 
the skin, muscle, and skeletal tissue [7-9].  
The model makes the following assumptions: 
1. Ingested water and Na+ enter the blood compartment, and excreted water 
and Na+ exit from the blood compartment. 
2. Na+ and water move freely between the IF and blood compartments across 
Na+ concentration gradients. 
3. Blood and IF compartments equilibrate quickly. 
4. Na+ intake is constant.  
5. When blood Na+ concentration exceeds the normal equilibrium level, there 
is a feedback to enhance water intake representing the effects of 
vasopressin-stimulated thirst. In response to increased diuresis, the 
increase in water intake is constrained to be less than 50% of the increase 
in water excretion[17]. 
6. When IF Na+ concentration exceeds the normal equilibrium level, Na+ 
moves out of the IF and is sequestered in the peripheral Na+ compartment, 
where it is osmotically inactive. This process happens very fast, on the 
same order as Na+ and water equilibration between the blood and IF. 
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The final two assumptions are required to be consistent with the observed constant 
plasma Na+ concentrations in the healthy volunteer study, as well as prior knowledge of 
the response to loop diuretics: that increased water intake accounts for up to 50% of the 
water deficit due to excretion[17].  See supplement for model equations, parameters, and 
additional explanation.  
 
The model inputs are the time courses of water and Na+ intake and excretion. Once 
excretion and intake are specified, the amount of Na+ and water in each compartment, 
the concentration gradient between compartments, and the Na+ and water moving 
between each compartment can be calculated over time.  
 
RESULTS  
Data for urine excretion and serum concentrations of sodium and glucose, as well as 
urine volume and serum potassium excretion, are summarized in Figure 2. As shown in 
Figure 3A, while total FWC tended to decrease over time with both treatments, 
dapagliflozin increased cH2Oe on day one, and it then returned to baseline. By 
comparison, cH2Oe with bumetanide was not different from total FWC. The difference 
between FWC and cH2Oe with dapagliflozin is likely the result of increased glucose 
excretion (Figure 2) and the associated osmotic diuresis effect. In other words, 
dapagliflozin produced a greater relative increase water excretion than in Na+ excretion, 
compared to bumetanide. Plasma renin activity increased in the bumetanide arm but was 
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unchanged in the dapagliflozin arm, although the difference did not reach statistical 
significance (Figure 3B).  
Theoretical effect of water and Na+ excretion on blood and IF volume 
Before turning to modeling the specific effects of dapagliflozin and bumetanide-generated 
Na+ and water excretion on blood and IF volume, we first considered the following 
hypothetical test cases, in order to better understand the effects of water and Na+ 
excretion separately.  
Case 1: Response to an increase in water excretion without an increase in Na+ 
excretion. Figure 4A shows the simulated response to an increase in urinary water 
excretion with no change in Na+ excretion. Two subcases are shown – with and without 
osmotically inactive peripheral Na+ storage. When Na+ is not allowed to be stored 
peripherally, free water excretion increases blood Na+ concentration and decreases blood 
and IF volume acutely, but ultimately has no sustained effect on any of these variables. 
Essentially all water removed is eventually replaced, and the system ends up at the same 
steady state where it began. However, when peripheral Na+ storage is included in the 
model, an increase in free water clearance then results in a sustained reduction in IF 
volume. The acute changes in blood volume and blood Na+ concentration are much 
smaller and both eventually return to normal. This aligns with the proposed role of 
peripheral Na+ storage as a buffer to prevent large changes in blood volume and blood 
pressure [18].  
In both cases, increased water excretion (panel 1) initially causes blood Na+ 
concentration to begin to rise (panel 3). Quickly, water moves from the IF to the blood 
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(panel 4), and Na+ moves from the blood to the IF (panel 5), across the concentration 
gradient. Thus, IF Na+ concentration rises too and remains in near equilibrium with the 
blood.  When peripheral Na+ storage is included in the model, as IF concentration 
increases above normal, the higher concentration causes excess Na+ to move out of the 
IF into the periphery (Panel 6). This sequestering of Na+ in the periphery essentially 
removes Na+ from the IF, allowing the concentration to remain low, and reducing the 
water volume needed to maintain the equilibrium Na+ concentration.  
In summary, essentially, removal of free water from the blood causes water to move out 
of the IF into the blood, which would tend to raise IF sodium concentration, but as IF 
concentration begins to increase, excess Na from the IF is stored non-osmotically in the 
periphery, allowing IF to maintain the equilibrium concentration at a lower volume.  
Case 2: Response to an increase in Na+ excretion without an increase in water 
excretion. Figure 4B shows the opposite case – the simulated response to an increase 
in urinary Na+ excretion with no change in water excretion. This is a physiologically 
unlikely scenario, but is useful for understanding the system behavior. In this case, blood 
volume is decreased over time, while IF volume is predicted to increase. This occurs 
because as Na+ is excreted from the blood, blood Na+ concentration falls, and water 
moves out of the blood into the IF, while Na+ moves from the IF into the blood stream. IF 
Na+ concentration begins to fall, but this causes Na+ to be pulled from the osmotically 
inactive sodium stores in the periphery back into the IF, preventing it from falling further. 
Thus, ultimately, Na+ excreted from the blood stream is replaced by Na+ returned from 
peripheral storage. This extra Na+ in the IF allows water that moved from the blood to the 
IF to be held there, so that blood volume is reduced while IF is increased. 
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Case 3: Increases in both Na+ and water excretion. The first two cases represented 
the extremes. Figure 4C shows the response to an increase in urinary Na+ excretion with 
three different levels of increased water excretion. The orange, blue, and green lines 
correspond to a +1, 0, and -1 L change in 24-hour cH2Oe. In all cases, blood volume is 
predicted to be reduced to a similar degree. The change in IF volume, on the other hand, 
is dependent on the change in water excretion relative to Na+ excretion. When water 
excretion is large relative to Na+ (cH2Oe is increased), IF volume is greatly reduced, but 
when the ratio is smaller, IF volume decreases less or even increases. Thus, the model 
predicts that Na+ excretion determines the degree of blood volume depletion, while free 
water clearance (water excretion in excess of Na+) determines the degree of IF volume 
reduction. 
 
Comparison of blood and IF volume response to dapagliflozin and bumetanide 
We next sought to simulate the response to dapagliflozin and bumetanide, using the 
clinically observed water and Na+ excretion time profiles as model inputs. Water and Na+ 
excretion following treatment with dapagliflozin or bumetanide treatment were modeled 
as a decaying exponential, the shape of which was determined by least-squared fitting to 
the observed 24hr urine Na+ and urine volume (Figure 5A, first column). It was also 
necessary to account for two additional features of the excretion data. First, in both 
groups, sodium excretion on day 0 was less than expected, given that study subjects 
were given daily 110mEq sodium tablets beginning 2 days before the study began. By 
day 7, sodium excretion was consistent with this sodium intake. The initial lower sodium 
excretion is likely due to tolerability issues and reduced absorption of the salt tablet, since 
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diarrhea, nausea, and vomiting were more common in the first 3 days of the study.  To 
account for this, we modeled an increase in sodium intake from day 0 to day 1, which was 
then reflected in sodium excretion.  We repeated the simulations assuming constant 
sodium intake and matching either the slope or absolute of the rise in sodium and water 
excretion on day 1 (Suppl. Figures 1 and 2). Changing these assumptions had small 
quantitative effects on the predicted blood and IF volume changes, but did not alter the 
conclusions of the simulations.  
Secondly, in the bumetanide group, water excretion declined below baseline after an 
initial peak. It is unlikely that bumetanide directly reduces water excretion over time, but 
this may reflect a physiologic overcompensation in water retention. In Figure 5A, we 
modeled this as a gradual linear decrease in water intake after day 1. We repeated these 
simulations without accounting for this affect (Supplement Figure 3). Again, altering these 
assumptions produced small quantitative differences in volume changes, but did not 
affect the conclusions of the simulations.   
We then simulated the time courses of serum Na+ concentration, IF volume, blood 
volume, peripheral Na+ storage, and water intake in response to the empirically fitted 
changes in Na+ and water excretion. As shown in Figure 5A, the model predicted that 
dapagliflozin reduces IF volume three times as much as blood volume (480 ml vs 150 
ml). In comparison, the predicted reduction in IF volume with bumetanide was only 80% 
of blood volume reduction (510 ml vs 780 ml) (Figure 5B).  Thus, while dapagliflozin 
produced an overall weaker natriuresis and diuresis than bumetanide, it is predicted to 
have a relatively greater effect on IF volume than on blood volume, compared to 
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bumetanide. In other words, SGLT2i may be able to effectively reduce interstitial 
congestion without causing arterial underfilling due to a large blood volume reduction.  
 
DISCUSSION 
In this study, we coupled observed plasma and urinary water and electrolyte data with a 
mathematical model to simulate and compare effects of dapagliflozin and bumetanide on 
blood volume and IF volume. In healthy volunteers, dapagliflozin produced similar 
changes in total free water clearance but a larger increase and smaller subsequent 
decrease in electrolyte-free water clearance than bumetanide. Although a role for urea 
cannot be ruled out since it was not measured, dapagliflozin-induced reductions in 
proximal tubule glucose reabsorption likely account for this different. Glucose remaining 
in the tubules draws water across the osmotic gradient, leaving sodium and other 
electrolytes behind.  
 
 
 
Our simulations suggest that the differential effect on electrolyte-free water clearance 
produces a relatively greater reduction in IF volume than in blood volume with 
dapagliflozin, compared to bumetanide. This differential effect on fluid compartments has 
potential therapeutic implications, particularly in heart failure. Heart failure is of course 
characterized by fluid accumulation, leading to peripheral and pulmonary edema. 
Managing congestion is a major goal in treating heart failure, and is achieved primarily 
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through use of loop diuretics. It also is a major challenge, because excessive blood 
volume reduction can have deleterious effects, including reduced arterial filling and organ 
perfusion, hypotension, and neurohormonal activation [13-16]. Neurohormonal activation, 
in turn, can cause greater sodium and water retention and reduced peripheral and renal 
perfusion due to vasoconstriction. Reduced renal blood flow may lead to renal impairment 
and further impairment in the ability to eliminate sodium and water. It has even been 
postulated that the higher mortality associated with high-dose loop diuretic use might be 
related to these effects (although cause and effect has not been established and these 
observations could also reflect confounding due to more severely ill patients requiring 
larger doses of diuretics) [19]. Although changes in PRA in the current healthy volunteer 
study were small, the fact that PRA increased with bumetanide but was unchanged with 
dapagliflozin is supportive of less neurohormonal activation with SGLT2i compared to 
loop diuretics. Few other data exist on the neurohumoral effects of SGLT2i and these 
have been collected in uncontrolled studies; however, the available data do not show 
activation of the renin-angiotensin system with SGLT2i which, if correct, is distinct from 
observations with conventional diuretics[20, 21].  
If our model is correct and SGLT2i indeed produces larger reductions in IF volume relative 
to blood volume, they may more effectively relieve signs and symptoms of interstitial 
congestion, and provide some relief of elevated cardiac filling pressures, without 
deleterious effects of excessive blood volume depletion, including neurohumoral 
activation. These effects should occur soon after initiating treatment. It is tempting to 
speculate that the diuretic and natriuretic action of SGLT2i were related to the heart failure 
hospitalization prevention noted in EMPAREG-OUTCOME (empagliflozin) and CANVAS 
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(canagliflozin), although other hypotheses have also been proposed to explain this 
benefit[4]. Treatment with empagliflozin and canagliflozin also significantly reduced the 
rate of renal function decline, an effect that may also contribute to the protective effect of 
these drugs in heart failure. However, treatment with SGLT2i initially decreases in GFR, 
making it unlikely that renoprotection accounts for the rapid reduction in heart failure 
hospitalization seen with SGLT2i (although their renoprotective actions may contribute to 
the long-term cardiovascular benefits). 
A critical component of the hypothesis of differential volume regulation proposed here is 
the ability of peripheral tissue to sequester Na+ when excess water relative to Na+ is 
removed and IF concentrations rise, and release Na+ when the opposite occurs. The 
importance of peripheral Na+ storage is increasingly recognized. In separate studies by 
Titze et al, reductions in peripheral Na+ (measured by Na-MRI) were greater with 
furosemide [8] than with dapagliflozin [10]. However, these studies are not directly 
comparable, since the first evaluated heart failure and patients and the second was in 
diabetic patients, and baseline peripheral sodium was quite different between the two 
studies. In addition, the dynamics of peripheral Na+ storage are incompletely understood, 
and there may be differences in peripheral Na+ storage between health and disease. Skin 
sodium content has been shown to be correlated with LV hypertrophy in chronic kidney 
disease[22]. Research is needed to fully understand the role of peripheral Na+ storage in 
regulating IF volume in health and disease. 
The hypothesis proposed here arises from predictions of IF and volume changes based 
on sodium and water excretion. Unfortunately, few studies have directly measured IF 
volume following treatment with SGLT2 inhibitors or loop diuretics, and no study has 
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directly compared the two. Hirose and colleagues did find that after 8 weeks of treatment 
with SGLT2i tofogliflozin, IF volume in patients with type 2 diabetes was significantly 
reduced by 400ml – similar to the reduction predicted by our simulations[23].  These 
investigators also reported significant reductions in body weight and free fat mass. 
Hematocrit increased, while mean arterial pressure was reduced slightly. Studies that 
more direct measure changes in IF and blood volume with these treatments are needed 
to validate the hypothesis.  
This study utilized data from healthy volunteers. Based on knowledge of the mechanism 
of action of each drug, it may be reasonable to assume that the relative difference in 
cH2Oe, and thus in relative IF volume reduction, will maintained in diseased states like 
heart failure. However, alterations in fluid status, renal function, and neurohumoral 
activation in diabetes and/or heart failure could impact the magnitude of the response. 
Studies in diabetic and heart failure patients should be conducted to further evaluate the 
hypothesis presented here. 
Diuretics like bumetanide and dapagliflozin stimulate thirst, and thus increased water 
intake may compensate for some of the electrolyte-free water loss. Unfortunately, 
changes in water intake were not measured in this study, and therefore, we cannot rule 
out that any excess in water excretion was compensated by increased intake. However, 
this seems unlikely. Rats treated with furosemide have been shown to replace less than 
half of the deficit in fluid volume by increasing intake[17].  
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The unexpectedly low sodium excretion at baseline in both study arms, as well as the 
decline over time in water excretion in the bumetanide arm, introduced some uncertainty 
into the simulations. We attempted to address this by testing alternative hypotheses to 
explain these data (see supplement). These alternative simulations did not alter the 
conclusions regarding the greater relative effect of SGLT2i on IF volume, compared to 
bumetanide.  
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Figure 1. Schematic of mathematical model of volume homeostasis.  
Figure 2. Observe urinary sodium excretion (top left), serum sodium  concentration(top right), 
urinary glucose excretion (middle left), serum glucose (middle right), urine volume (bottom left), 
and urinary potassium excretion (bottom right) during daily dosing of dapagliflozin or bumetanide. 
Data are mean (solid lines) and 25th and 75th quartiles. 
 
Figure 3.  Observed mean change in electrolyte-free water clearance clearance (cH20e) and total 
free water clearance (FWC) (A) and plasma renin activity (PRA) (B) following initiation of 
treatment with dapagliflozin or bumetanide. FWC and cH20e were not different in the 
bumetanide arm. In the dapagliflozin arm, cH20e was higher than FWC, which decreased over 
time.Dapagliflozin tended to produce a larger initial increase and smaller subsequent decrease in 
electrolyte-free water clearance than bumetanide. Although the differences were not statistically 
significant,  plasma renin activity tended to increase with bumetanide but not dapagliflozin.  
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Figure 4. Hypothetical response to imposed changes in urinary volume excretion (first column) 
and urinary Na+ excretion (second column). A) Response to increase in water excretion without 
an increase in Na+ excretion, when peripheral Na+ storage is excluded (orange) or included 
(green) in the model. Without peripheral storage, water excretion has no sustained effect. With 
peripheral storage, water excretion causes a sustained decrease in IF volume, with no change in 
blood volume. B) An increase in Na+ excretion with no change in water excretion is predicted to 
produce a sustained blood volume reduction with no change in IF volume. C) The change in IF 
volume is dependent on the relative increase in water excretion compared to Na+ excretion. 
 
Figure 5. (A-B) Simulated volume responses to the increases in Na+ and water excretion 
observed with dapagliflozin (A) and bumetanide (B). The first column in each panel shows the 
urinary Na+ and water excretion profiles used as input to the model. The next three panels show 
the simulated electrolyte free water clearance, plasma Na+ concentration, blood volume, and IF 
volume. Solid lines – simulation. Thick dashed lines (first column only) – simulated intake. 
Circles – mean observed data. Dashed gray lines – observed 25th and 75th quantiles.  C-D) 
Dapagliflozin is predicted to produce a 3-fold decrease in IF volume relative to blood volume, 
while the reduction in IF with bumetanide is only 66% of the reduction in blood volume. 
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